Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07782333
Recruiting Phase 2

A Study Evaluating TRIV-573 in Atopic Dermatitis

NCT07782333 · tracked via the Priya Life Science USA tracker
Sponsor
Triveni Bio
Phase
Phase 2
Started
2026-09-09
Last updated
2026-10-28

Condition(s) studied

Atopic Dermatitis

Investigational drug(s) / intervention(s)

TRIV-573Placebo

TRIV-573: TRIV-573 (Subcutaneous injection)

Placebo: Placebo (Matching Placebo subcutaneous injection)

Study summary

The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573.

Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo).

The study duration for individual participants is up to 40 weeks, including a Screening period of up to 30 days.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Has Atopic Dermatitis. * Has moderate to severe, active and symptomatic atopic dermatitis. Exclusion Criteria: * Severe or uncontrolled medical conditions. * Use of prohibited medications within stated washout periods.

Primary outcome measure(s)

  • Percentage of participants with improvement of AD — Baseline through Week 16

Trial sites (17)

FacilityCityRegionStatus
Triveni Bio Site #15 Fountain Valley California Recruiting
Triveni Bio Site #4 Los Angeles California Recruiting
Triveni Bio Site #11 Boca Raton Florida Recruiting
Triveni Bio Site #7 Miami Florida Recruiting
Triveni Bio Site #3 Miami Florida Recruiting
Triveni Bio Site #2 Indianapolis Indiana Recruiting
Triveni Bio Site #13 Bay City Michigan Recruiting
Triveni Bio Site #16 Boardman Ohio Recruiting
Triveni Bio Site #1 Camp Hill Pennsylvania Recruiting
Triveni Bio Site #14 Myrtle Beach South Carolina Recruiting
Triveni Bio Site #9 San Antonio Texas Recruiting
Triveni Bio Site #6 San Antonio Texas Recruiting
Triveni Bio Site #8 Spokane Washington Recruiting
Triveni Bio Site #17 Calgary Alberta Recruiting
Triveni Bio Site #5 Barrie Ontario Recruiting
Triveni Bio Site #12 Ivano-Frankivsk Ukraine Recruiting
Triveni Bio Site #10 Kyiv Ukraine Recruiting

More Triveni Bio trials in the USA

A Study Evaluating TRIV-509 in Atopic Dermatitis Active, not recruiting

Other trials for the same condition

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis Active, not recruiting
Investigating Participation Patterns of Patients in Atopic Dermatitis Clinical Trials Starting soon
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis Active, not recruiting
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares Recruiting
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07782333 on ClinicalTrials.gov ↗ ← All trials in the USA